RegenXBio (RGNX) Receives a Rating Update from a Top Analyst

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on RegenXBio (RGNX), with a price target of $150.00. The company’s shares closed last Monday at $44.54.

According to TipRanks.com, Amusa is a top 100 analyst with an average return of 26.9% and a 52.6% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Catalyst Biosciences, and Evelo Biosciences.

RegenXBio has an analyst consensus of Strong Buy, with a price target consensus of $77.50, representing a 77.5% upside. In a report issued on January 17, Morgan Stanley also maintained a Buy rating on the stock with a $58.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $63.21 and a one-year low of $30.38. Currently, RegenXBio has an average volume of 465.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.